Support for the Rhabdomyolysis in an Emergency Department

Status Withdrawn

Clinical Trial Summary

Rhabdomyolysis is a common condition in the UAA. Support is heterogeneous, it is in most cases a mass hyperhydration. The idea is to initially with an EPP simultaneously screened for the most affected by this disease and aggravating factors population, associated comorbidities.

The rhabdomyolysis prognosis depends mainly on the etiology and associated comorbidities.

- Acute renal failure and hyperkalemia are the major complications that worsen the prognosis.

- In most cases, acute renal failure is reversible. Acute renal failure caused by renal vasoconstriction with ischemia, precipitation of myoglobin in the tubules and direct cytotoxic action of myoglobin.

If the prime mover of rhabdomyolysis is ischemia (or hypoxia) cell, we now know that the tissue damage is greatly aggravated during muscle reperfusion, creating ischemia-reperfusion. Reperfusion will not only cause the release into the bloodstream of the cell contents myocytes but also an increase in necrotic areas. Indeed, the massive arrival of oxygen at the myocyte will cause significant production of free radicals, increasing their toxic effects.

Predictive factors of acute renal failure is creatinine and urea. The urine alkalinisation by bicarbonates is questionable oral alkalizing seems to be an alternative when possible (oral alkaline solution) but not used to this day.

The track N-acetyl cysteine as an antioxidant that can possibly have an effect on release of the free radicals during reperfusion by decreasing their toxicity is still not considered clinically.

Clinical Trial Description

Main objective / secondary:

Evaluation of current professional practice:

I. Identify the most common etiologies encountered in our SAU. II. Identify the / types of people most affected by this disease III. Detect the most common complications of H0 support and evolution H48 if the patient not transferred IV. Evaluate the emergency treatment at the initial charge.

Methodology :

DESIGN:

It is a non-interventional retrospective single-center study, within the Department of Emergency GHPSJ, to an EPP and output the results regarding the type of population most affected by this disease with the most common etiologies in our support (what we are doing).

Time study:

Study on patient records being passed on to the emergency 12 months out with a diagnosis of rhabdomyolysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02896517
Study type	Observational
Source	Groupe Hospitalier Paris Saint Joseph
Contact
Status	Withdrawn
Phase
Start date	October 1, 2016
Completion date	October 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03737513` - Exercise-induced Collective Rhabdomyolysis
Completed	`NCT00241748` - Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event	N/A
Not yet recruiting	`NCT02498366` - Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty	N/A
Not yet recruiting	`NCT06429982` - Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols	Phase 1
Active, not recruiting	`NCT06101680` - RhabdomYolyse in Intensive caRe
Completed	`NCT01467180` - Myoglobin Removal by High Cut-off CVVHD	N/A
Recruiting	`NCT01022450` - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients	N/A
Completed	`NCT00391911` - Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis	Phase 2
Withdrawn	`NCT02111018` - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis	Phase 2
Completed	`NCT04913298` - Prospective Study for the Application of Cytosorb® in Critically Ill Patients	N/A
Recruiting	`NCT05146336` - CytOSorb TreatMent Of Critically Ill PatientS Registry
Completed	`NCT03986736` - Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma
Not yet recruiting	`NCT02518724` - The Effect of Remote Ischemic Preconditioning on Physical Performance and Exertional Rhabdomyolysis	N/A
Completed	`NCT02671604` - Rhabdomyolysis and Robot-assisted Radical Prostatectomy	N/A
Completed	`NCT00592657` - Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions	N/A
Completed	`NCT06338423` - Use of a Vacuum Mattress During Laparoscopic Sleeve Gastrectomy to Reduce the Concentration of Rhabdomyolysis Markers and Acute Renal Failure	N/A
Completed	`NCT01976936` - Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2	Phase 2
Completed	`NCT04118608` - Rhabdomyolysis - a Study of Patient Characteristics and Laboratory Values to Guide Treatment
Completed	`NCT01544231` - Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis	N/A
Recruiting	`NCT00549029` - The Association of Genetic Polymorphisms With Statin-Induced Myopathy.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Support for the Rhabdomyolysis in an Emergency Department — RHABDURGENCE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms